On May 9, 2024, T2 Biosystems, Inc., a medical diagnostic company, experienced a significant change in its ownership structure as detailed in an amended Schedule 13D filing with the U.S. Securities and Exchange Commission. The filing indicates that a group led by Nathan D. Hukill, including entities such as CR Group L.P. and various CRG Partners funds, has acquired a substantial portion of the company's common stock. The shares were obtained in exchange for the cancellation of outstanding loans previously extended to T2 Biosystems under a Term Loan Agreement dating back to December 30, 2016. As a result of these transactions, the group collectively holds approximately 69.5% of the issued and outstanding shares of T2 Biosystems' common stock. This percentage includes shares acquired through the conversion...Show More

On May 9, 2024, T2 Biosystems, Inc., a medical diagnostic company, experienced a significant change in its ownership structure as detailed in an amended Schedule 13D filing with the U.S. Securities and Exchange Commission. The filing indicates that a group led by Nathan D. Hukill, including entities such as CR Group L.P. and various CRG Partners funds, has acquired a substantial portion of the company's common stock. The shares were obtained in exchange for the cancellation of outstanding loans previously extended to T2 Biosystems under a Term Loan Agreement dating back to December 30, 2016. As a result of these transactions, the group collectively holds approximately 69.5% of the issued and outstanding shares of T2 Biosystems' common stock. This percentage includes shares acquired through the conversion of Series A and Series B Convertible Preferred Stock on May 9, 2024. The filing also notes that no other transactions in the common stock have been made by the reporting persons in the last 60 days, and no other person is known to have the right to receive dividends or proceeds from the sale of the shares owned by the reporting group.